||||Page||
|---|---|---|---|---|
|Report of the Trustees||I|to|4|
|Independent<br>Examiner's|Report||||
|Statement<br>of Financial|Activities||||
|Balance Sheet||7|to|8|
|Notes to the Financial Statements||9|to|l5|
|Detailed Statement<br>ofFinancial Activities|||16||





## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 




|Registered<br>office||||||
|---|---|---|---|---|---|
|Executive Business Support||||||
|Davidson<br>Road||||||
|Lichfield||||||
|Staffordshire||||||
|WSI49DZ||||||
|Trustees||||||
|Professor<br>M Heneghan<br>Consultant<br>Hepatologist|(resigned|24.9.22)||||
|Professor B R Davidson<br>Hepatobiliary<br>and Transplant<br>Consultant||||||
|DrJW Ferguson<br>Consultant<br>Hepatologist<br>(resigned 24.9.22)||||||
|Dr TJ Kendall Senior Clinical Fellow In Pathology||||||
|Dr I A C Rowe University<br>Clinical Academic Fellow||||||
|Dr S M Rushbrook<br>Consultant<br>Gastroentrologist|(resigned|24.9.22)||||
|Dr V Snowdon<br>Consultant<br>Hepatologist||||||
|Ms M BClayton<br>Lecturer<br>In Liver Care||||||
|Dr M A Aldersley<br>Consultant<br>Hepatologist<br>(resigned<br>l.2.23)||||||
|Dr KJ Simpson<br>Consultant<br>Physician<br>and Senior|Lecturer|||||
|Dr V R Aluvihare<br>Transplant<br>Hepatologist<br>(resigned 24.9.22)||||||
|Professor<br>F Oakley Professor of Fibrosis Biology|(resigned|24.9.22)||||
|Professor<br>M E Cramp Consultant<br>Hepatologist<br>(appointed||23.9.22)||||
|Dr A M Elsharkawy<br>Consultant<br>Hepatologist<br>(appointed 23.9,22)||||||
|Dr RJones Consultant<br>Hepatologist||||||
|Dr K Drysale Hepatolgy<br>Registrar<br>Clinical Research (resigned|||3I.I.23)|||
|Professor R Mookerjee Professor ofTranslational|Hepatology||(appointed||23.9.22)|
|Dr M Allison Consultant<br>Hepatologist<br>(appointed|23.9.22)|||||
|Dr S Chokshi<br>Acting Director &Chief Scientific|Offic (appointed|||23.9.22)||





## 

## 

## 

## 



## 

## 

## 

||||||||2022|2021|
|---|---|---|---|---|---|---|---|---|
||||||Unrestricted|Restricted|Total|Total|
||||||funds|funds|funds|funds|
||||Notes||||||
|INCOME AND ENDOWMENTS|||FROM||||||
|Membership<br>subscriptions|||||99,160||99,160|94,339|
|Conference fees &sponsorship||income|||297,904||297,904|128,371|
|Interest receivable|||||828||828|748|
|Total|||||397,892||397,892|223,458|
|EXPENDITURE ON|||||||||
|Conference costs|||||||||
|Direct conference costs|||||206,048||206,048|43,461|
|Other associated conference|costs||||197,398||197,398|117,442|
||||||403,446||403,446|160,903|
|Other|||||13,476||13,476||
|Total|||||416,922||416,922|160,903|
|NET INCOME/(EXPENDITURE)|||||(19,030)||(19,030)|62,555|
|RECONCILIATION<br>OF|FUNDS||||||||
|Total funds brought forward|||||144,031|22,377|166,408|103,853|
|TOTAL FUNDS CARRIED||FORWARD|||125,001|22,377|147,378|166,408|
|CONTINUING<br>OPERATIONS|||||||||
|All income and expenditure|has|arisen|from continuing|activities.|||||





## 

||||||Balance Sheet|Balance Sheet||||
|---|---|---|---|---|---|---|---|---|---|
||||||31 DECEMBER 2022|||||
|||||||||2022|2021|
|||||||Unrestricted|Restricted|Total|Total|
|||||||funds|funds|funds|funds|
||||||Notes|||f||
|FIXEDASSETS||||||||||
|Investments|||||12|||||
|CURRENT ASSETS||||||||||
|Debtors: amounts||falling due within one year|||13|17,893||17,893|14,464|
|Cash ar. bank||||||184,360|22,377|206,737|211,358|
|||||||202,253|22,377|224,630|225,822|
|CREDITORS||||||||||
|Amounts<br>falling|due||within|one year|14|(45,129)||(45,129)|(28,029)|
|NET CURRENT||ASSETS||||157,124|22,377|179,501|197,793|
|TOTAL ASSETS|||LESS|CURRENT||||||
|LIABILITIES||||||157,125|22,377|179,502|197,794|
|CREDITORS||||||||||
|Amounts<br>falling|due||after more than one year||15|(32,124)||(32,124)|(31,386)|
|NET ASSETS||||||125,001|22,377|147,378|166,408|
|FUNDS|||||16|||||
|Unrestricted<br>funds:||||||||||
|General<br>fund||||||||125,001|144,031|
|Restricted<br>funds:||||||||||
|BASL nurses|fund|||||||6,627|6,627|
|CCA UK Neil Blenkinsop||||donation for research||||15,750|15,750|
|only||||||||||
|||||||||22,377|22,377|
|TOTAL FUNDS||||||||147,378|166,408|





## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 




## 

## 

## 

||||2022|202I|
|---|---|---|---|---|
||||E||
||Interest receivable||828|748|
|6.|DIRECT CONFERENCE COSTS||||
||||2022|202I|
||Annual<br>conference costs||I94,548|25,248|
||Annual<br>support to UKLA||I l,500|I I,500|
||Support costs|||6,7 I3|
||||206,048|43,46 I|
|7.|OTHER ASSOCIATED|CONFERENCE COSTS|||
||||2022|2021|
|||||E|
||Travel & hotels||2,242|584|
||Artwork/design<br>& print||3,536|I I5|
||CPD application||284|56I|
||Bank charges||4, I96|4,8I4|
||Website||6,I85|4,507|
||Secretarial support costs||5,75 I|4,004|
||EBSCosts||175,204|I40,275|
||Credit release - Swansea HE|||(37,4 I8)|
||||I97,398|I I7,442|
|8.|SUPPORT COSTS||||
|||||Governance|
|||||costs|
||Other resources expended|||l3,476|
|9.|NET INCOME/(EXPENDITURE)||||
||Net income/(expenditure)|is stated after charging/(crediting):|||
||||2022|202 I|
||Accountancy<br>fees||5,047|4,020|





## 

## 

## 

||||||Unrestricted|Restricted|Total|
|---|---|---|---|---|---|---|---|
||||||funds|funds|funds|
||||||f.|f||
||INCOME AND ENDOWMENTS|||FROM||||
||Membership<br>subscriptions||||94,339||94,339|
||Conference fees &sponsorship||income||128,371||128,371|
||Interest receivable||||748||748|
||Total||||223,458||223,458|
||EXPENDITURE ON|||||||
||Conference costs|||||||
||Direct conference costs||||43,461||43,461|
||Other associated conference costs||||117,442||117,442|
||||||160,903||160,903|
||NET INCOME||||62,555||62,555|
||RECONCILIATION|OF FUNDS||||||
||Total funds brought forward||||81,476|22,377|103,853|
||TOTAL FUNDS CARRIED||FORWARD||144,031|22,377|166,408|
|12.|FIXEDASSET INVESTMENTS|||||||
||||||||Unlisted|
||||||||investments|
||MARKET VALUE|||||||
||At<br>I January 2022 and 31 December 2022|||||||
||NET BOOKVALUE|||||||
||At 31 December 2022|||||||
||At 31 December 2021|||||||





## 

## 

## 

||||||2022|2021|
|---|---|---|---|---|---|---|
|||||||E|
|Trade debtors|||||17,500|10,062|
|VAT||||||4,029|
|Prepayments|||||393|373|
||||||17,893|14,464|
|CREDITORS: AMOUNTS|||FALLING DUE WITHIN ONE YEAR||||
|Deferred|income||||||
|||||2022||2021|
|||||E.||E|
|Deferred|income at|I January|2022|14,000||0|
|Resources|deferred|during the year||20,300||14,000|
|Amounts|released from prior||year|(14,000)||0|
|Deferred|income|at 31 December 2022||20,300||14,000|



## 

## 

## 

|15.|CREDITORS|:|AMOUN|TS<br>FALLING DU|E AFTER MORE TH|AN ONE YEAR|||
|---|---|---|---|---|---|---|---|---|
||||||||2022|2021|
||Bursary<br>Fund -||support for members to attend||meetings||20,381|19,643|
||Swansea health||economics|work to accompany|HCCUK Projec||(736)|(736)|
||BLNA restricted||fund||||12,479|12,479|
||||||||32,124|31,386|
|16.|MOVEMENT||IN FUNDS||||||
||||||||Net||
||||||||movement|At|
|||||||At 1.1.22|in funds|31.12.22|
||Unrestricted|funds|||||||
||General<br>fund|||||144,031|(19,030)|125,001|
||Restricted funds||||||||
||BASL nurses fund|||||6,627||6,627|
||CCA UK Neil|Blenkinsop||donation for|||||
||research<br>only|||||15,750||15,750|
|||||||22,377||22,377|
||TOTAL FUNDS|||||166,408|(19,030)|147,378|





## 

## 

|Net movement|in funds,|included|in the above are as follows:||||
|---|---|---|---|---|---|---|
|||||Incoming|Resources|Movement|
|||||resources|expended|in funds|
|Unrestricted|funds||||||
|General<br>fund||||397,892|(416,922)|(19,030)|
|TOTAL FUNDS||||397,892|(416,922)|(19,030)|
|Comparatives|for movement||in funds||||



||||||Net||
|---|---|---|---|---|---|---|
||||||movement|At|
|||||At 1,1.21|in funds|31.12.21|
|||||||f|
|Unrestricted|funds||||||
|General<br>fund||||81,476|62,555|144,031|
|Restricted funds|||||||
|BASL nurses|fund|||6,627||6,627|
|CCA UK Neil Blenkinsop||donation|for||||
|research<br>only||||15,750||15,750|
|||||22,377||22,377|
|TOTAL FUNDS||||103,853|62,555|166,408|



||||Incoming|Resources|Movement|
|---|---|---|---|---|---|
||||resources|expended|in funds|
||||||E|
|Unrestricted||funds||||
|General|fund||223,458|(160,903)|62,555|
|TOTAL FUNDS|||223,458|(160,903)|62,555|





## 



## 

## 

||for the<br>ear ended 31 DEC|EMBER 2022||
|---|---|---|---|
|||2022|2021|
||||E|
|INCOME AND ENDOWMENTS||||
|Membership<br>subscriptions||||
|Donations|||160|
|Subscriptions||99,160|94,179|
|||99,160|94,339|
|Conference fees &sponsorship|income|||
|Conference<br>income||297,904|128,371|
|Interest receivable||||
|Interest receivable||828|748|
|Total incoming resources||397,892|223,458|
|EXPENDITURE||||
|Direct conference costs||||
|Annual<br>conference costs||194,548|25,248|
|Annual<br>support to UKLA||11,500|11,500|
|||206,048|36,748|
|Other associated conference costs||||
|Travel<br>8c hotels||2,242|58¹|
|Artwork/design<br>&print||3,536|115|
|CPD application||284|561|
|Bank charges||4,196|4„814|
|Website||6, 185|4,507|
|Secretarial support costs||5,751|4,004|
|EBSCosts||175,204|140,275|
|Credit release - Swansea HE|||(37,418)|
|||197,398|117,442|
|Support costs||||
|Governance<br>costs||||
|Accountancy<br>fees||5,047|4,020|
|Other<br>legal and professional||8,429|2,693|
|||13,476|6,713|
|Total resources<br>expended||416,922|160,903|
|Net (expenditure)/income||(19,030)|62,555|



